U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
  1. Drug Approvals and Databases

Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)

The Orange Book

The publication Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act) and related patent and exclusivity information. For more information on the Orange Book including its history, see the Orange Book Preface.

Search the Orange Book Database
Search approved drug products by active ingredient, proprietary name, applicant, application number, dosage form, route of administration or patent number.
One-time report on marketing status for all ANDAs and NDAs required by FDARA section 506I(c) was due February 14, 2018. More information
<div class="lcds-card-deck bg-light-gray" style="text-align: left; margin-bottom: 1rem;">

Did you ever wonder how the Orange Book got its nickname?

When the first print edition of Approved Drug Products with Therapeutic Equivalence Evaluations was being prepared October 1980, staff members in the Office of Generic Drugs had to choose a color for the cover. The project manager suggested, "It's almost Halloween. How about orange?"

Before long, The Orange Book had become a popular short title for this important publication.

Orange Book Publications

Additional Resources

Contact Us

The Orange Book downloadable data files are updated monthly. We make every effort to prevent errors and discrepancies in the Approved Drug Products data files; however, if you wish to report an error or discrepancy in drug data, please send a brief description of the problem to orangebook@fda.hhs.gov.

General questions related to the drug data in these files should be directed to the Center for Drug Evaluation and Research, Division of Drug Information druginfo@fda.hhs.gov.

Requests for more specific information should be submitted in writing or directed to the FDA's Freedom of Information (FOIA) Staff.

 

 

Back to Top